Cingulate (CINGW) Liabilities and Shareholders Equity (2021 - 2026)
Cingulate's (CINGW) quarterly Liabilities and Shareholders Equity came in at $33.1 million in Q2 2026, up 119.37% quarter-over-quarter from $15.1 million in Q4 2025.
Analysis
Cingulate (CINGW) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $33.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $33.1 million; the trailing twelve-month figure through Jun 2026 stood at $58.7 million (up 43.37% YoY), and the FY2025 full-year result was $15.1 million, up 1.4% from the prior year.
- Liabilities and Shareholders Equity rose to $33.1 million in Q2 2026 per CINGW's latest filing, from $15.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $33.1 million in Q2 2026 and bottomed at $3.5 million in Q4 2023.
- Historically, Liabilities and Shareholders Equity has averaged $11.9 million across 5 years, with a median of $11.9 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 69.39% in 2023, then soared 325.74% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $11.4 million in 2022, then tumbled by 69.39% to $3.5 million in 2023, then jumped by 325.74% to $14.9 million in 2024, then climbed by 1.4% to $15.1 million in 2025, then soared by 119.37% to $33.1 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $33.1 million, $15.1 million, and $10.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 150.01 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 4.32 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 7.87 Bn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | 7.22 Bn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 33.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.07 Mn |
| Dec 31, 2025 | 15.07 Mn |
| Sep 30, 2025 | 10.52 Mn |
| Mar 31, 2025 | 12.47 Mn |
| Dec 31, 2024 | 14.86 Mn |
| Sep 30, 2024 | 13.58 Mn |
| Jun 30, 2024 | 5.13 Mn |
| Mar 31, 2024 | 5.49 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Sep 30, 2023 | 5.87 Mn |
| Jun 30, 2023 | 5.23 Mn |
| Mar 31, 2023 | 7.16 Mn |
| Dec 31, 2022 | 11.41 Mn |
| Sep 30, 2022 | 15.38 Mn |
| Jun 30, 2022 | 13.80 Mn |
| Mar 31, 2022 | 18.43 Mn |
| Dec 31, 2021 | 22.89 Mn |